Download PDF
Diabetes aktuell 2023; 21(03): 123-132
DOI: 10.1055/a-2069-1968
Schwerpunkt

Diabetestherapie bei herzkranken Patienten

Orale Antidiabetika und Glucagon-like Peptide 1 (GLP-1)-Rezeptoragonisten
Baptist Gallwitz
1   Medizinische Klinik IV (Diabetologie, Endokrinologie, Nephrologie), Universitätsklinikum Tübingen, Tübingen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Wenn es nicht möglich ist, die glykämischen Behandlungsziele mit nicht-medikamentösen Maßnahmen zu erreichen, soll innerhalb weniger Monate – oder bei Stoffwechseldekompensation sofort – mit einer medikamentösen Diabetestherapie begonnen werden. Dabei müssen individualisierte Therapieziele unter Einbezug des individuellen kardiovaskulären und renalen Risikos definiert werden.



Publication History

Article published online:
10 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 American Diabetes Association Professional Practice Committee Draznin B, Aroda VR. et al 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 2022; 45 (Suppl. 01) S125-S143
    Search in Google Scholar
  • 2 Buse JB, Wexler DJ, Tsapas A. et al Correction to: 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 2020; 63: 1667
    CrossrefPubMedSearch in Google Scholar
  • 3 Landgraf R, Aberle J, Birkenfeld AL. et al Therapie des Typ-2-Diabetes. Diabetologie 2022; 17 (Suppl. 02) S159-S204
    Thieme ConnectSearch in Google Scholar
  • 4 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Teilpublikation der Langfassung. 2. Auflage. Version 1. www.leitlinien.de/diabetes 2021 (letzter Zugriff: 06.04.2023)
    CrossrefSearch in Google Scholar
  • 5 Cosentino F, Grant PJ, Aboyans V. et al 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323
    Search in Google Scholar
  • 6 UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865
    CrossrefPubMedSearch in Google Scholar
  • 7 Breuer TG, Meier JJ. Inpatient treatment of type 2 diabetes. Dtsch Arztebl Int 2012; 109: 466-474
    CrossrefPubMedSearch in Google Scholar
  • 8 Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017; 60: 1586-1593
    CrossrefPubMedSearch in Google Scholar
  • 9 Rote-Liste-Service-GmbH. Fachinformationsverzeichnis Deutschland. http://www.fachinfo.de (letzter Zugriff: 06.04.2023)
  • 10 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungsleitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter – Kurzfassung Version 1.4.2012. http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro/index_html (letzter Zugriff: 06.04.2023)
  • 11 Eurich DT, Majumdar SR, McAlister FA. et al Improved clinical outcomes associated withmetformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351
    CrossrefPubMedSearch in Google Scholar
  • 12 McGill JB. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. Curr Diabetes Rev 2012; 08: 257-267
    CrossrefPubMedSearch in Google Scholar
  • 13 Bannister CA, Holden SE, Jenkins-Jones S. et al Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16: 1165-1173
    CrossrefPubMedSearch in Google Scholar
  • 14 Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010; 160: 8-19
    CrossrefPubMedSearch in Google Scholar
  • 15 Meier JJ, Gallwitz B, Schmidt WE. et al Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 2004; 90: 9-12
    CrossrefPubMedSearch in Google Scholar
  • 16 Bennett WL, Maruthur NM, Singh S. et al Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613
    CrossrefPubMedSearch in Google Scholar
  • 17 Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetesmellitus therapy. Expert Opin Investig Drugs 2011; 20: 723-732
    CrossrefPubMedSearch in Google Scholar
  • 18 Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne) 2019; 10: 389
    CrossrefPubMedSearch in Google Scholar
  • 19 Rosenstock J, Kahn SE, Johansen OE. et al Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019; 322: 1155-1166
    CrossrefPubMedSearch in Google Scholar
  • 20 Nauck MA, Quast DR, Wefers J. et al GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
    CrossrefPubMedSearch in Google Scholar
  • 21 Lee MMY, Kristensen SL, Gerstein HC. et al Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr 2022; 16: 102382
    CrossrefPubMedSearch in Google Scholar
  • 22 Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 08: 1335-1380
    CrossrefPubMedSearch in Google Scholar
  • 23 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
    Search in Google Scholar
  • 24 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
    CrossrefPubMedSearch in Google Scholar
  • 25 Cannon CP, Pratley R, Dagogo-Jack S. et al Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383: 1425-1435
    CrossrefPubMedSearch in Google Scholar
  • 26 Palmer SC, Tendal B, Mustafa RA. et al Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573
    CrossrefPubMedSearch in Google Scholar